Trial Profile
Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Paclitaxel (Primary) ; Cisplatin; Cyclophosphamide; Epirubicin
- Indications Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research
- 08 Jun 2021 Results of a 8 years of median follow-up analysis presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 11 Feb 2017 Status changed from recruiting to completed.